Need Help With This Product?
Our specialists are here to help you find the best product for your application.
Lamin A/C LMNA mutations are a common cause of dilated cardiomyopathy (DCM). Clinically, DCM is characterized by ventricular dilation concurrent with reduced systolic function and arrhythmias. A missense mutation in the gene encoding the lamin A/C protein (LMNA) results in a change of amino acid 35 from leucine-to-proline (L35P).
To enable researchers to study functional cardiac consequences, somatic cells from an individual carrying the LMNA L35P mutation were reprogrammed to generate MyCell® Cardiomyocytes DCM (L35P), 01016. In addition, an isogenic control, MyCell Cardiomyocytes Corrected DCM (L35P), was generated using genome engineering strategies to correct the mutation. MyCell Cardiomyocytes (L35P) display classic hallmarks of dilated cardiomyopathy including abnormal contractile properties (i.e. reduced contraction amplitude).
MyCell Cardiomyocytes (L35P) and its isogenic control (L35P Corrected) exhibit the relevant biology and functionality to advance research and preclinical studies for devastating congenital muscular dystrophies, laminopathies, and cardiomyopathies.
Representative phase contrast images (20X) of isogenic control and MyCell Cardiomyocytes (L35P) reveal comparable structure when plated at 20,000 cells per well in 96-well format. (DIV14)
Contractility was monitored by measuring impedance over time. MyCell Cardiomyocytes (L35P) display reduced contraction amplitude relative to isogenic control. (DIV 14)
Representative calcium transients reveal that MyCell Cardiomyocytes (L35P) display increase beat rate relative to isogenic control. (DIV 14)